Aim: Venous stasis is a well-known risk factor for the development of venous thromboembolism. It is likely that stasis increases the risk of thrombosis by inducing hypercoagulability via the hypoxic procoagulant activation of endothelial and mononuclear cells and the accumulation of activated clotting factors. However, increased rates of thrombin formation have not been demonstrated in response to venous stasis in vivo. Methods: In this study, we used the venous occlusion (VO) test to determine, if stasis triggers thrombin formation in healthy individuals (n = 25) and patients with additional thrombotic risk factors, such as inherited thrombophilia (n = 19) and symptomatic atherosclerosis (n = 15). Thrombin formation was monitored by measuring plasma levels of free thrombin using a highly sensitive oligonucleotide enzyme capture assay (OECA) in addition to the plasma levels of prothrombin fragment 1＋2 (F1＋2) and thrombin-antithrombin-complexes (TAT). The plasma levels of activated protein C (APC) were additionally measured using an APC-OECA. Results: VO induced a significant (p＜0.05) increase in the levels of tissue-type plasminogen activator and plasmin-α2-antiplasmin-complexes. In all three cohorts, the majority of samples obtained during VO showed no quantifiable thrombin or APC levels. Consistent with these findings F1＋2 and TAT did not change. Conclusions: We conclude that short-term venous stasis induces a profibrinolytic response due to the activation of endothelial cells, but not a prothrombotic response, even in the presence of additional thrombophilic risk factors. Furthermore, our results support the hypothesis that the stasis-induced profibrinolytic activation of endothelial cells occurs independently from thrombin formation. No Thrombin Formation in Short Stasis genetic risk factors are required to promote clot formation. Therefore, patients with hereditary thrombophilia and/or symptomatic atherosclerosis were included in this study.
Journal of Atherosclerosis and Thrombosis Vol. 21, No.12 Original Article paraplegic patients 2) . Moreover, immobilization during long distance travel increases the risk of DVT 3) . Stasis increases the risk of DVT likely via two primary mechanisms: (1) local hypoxia and (2) the accumulation of prothrombotic substances. Hypoxia triggers several adaptive responses in endothelial cells, monocytes and macrophages, thus inducing the activation of a variety of genes associated with coagulation and inflammation, resulting in a proinflammatory and procoagulant phenotype 4) . Simultaneously, the clearance of activated clotting factors and other prothrombotic substances is impaired due to stasis-induced blockade of the wash-out of these materials and the suppression of endogenous anticoagulant mechanisms 5) .
Introduction
Venous stasis is a key factor in the pathogenesis of venous thromboembolism. This is demonstrated by the observation that the risk of deep vein thrombosis (DVT) increases in parallel with the duration of bed rest 1) . Furthermore, DVT occurs more frequently in the paralyzed limb in hemiplegic patients than the unaffected limb and equally as often in both limbs in
Short-term Venous Stasis Induces Fibrinolytic Activation but not Thrombin Formation
Heiko Rühl 1 , Jens Müller 1 , Jana Wäschenbach 1 genetic risk factors are required to promote clot formation. Therefore, patients with hereditary thrombophilia and/or symptomatic atherosclerosis were included in this study.
Methods

Subjects
The study population consisted of healthy probands, coronary artery disease (CAD) patients and thrombophilic patients. The healthy probands had no history of cardiovascular disease, neurological disease or thromboembolic events. The patients with CAD had been referred to our hospital for coronary artery bypass surgery and were confirmed to have coronary atherosclerosis on coronary angiography. The thrombophilic patients were either homozygous for the FV Leiden mutation or prothrombin G20210A mutation or had congenital deficiencies of AT, protein C (PC) or protein S, as confirmed on molecular genetic analyses.
A total of 28 healthy probands, 15 CAD patients and 21 thrombophilic patients were eligible and agreed to join this study. Three healthy probands dropped out after developing orthostatic hypotension during venous occlusion. In addition, blood sampling was not successful due to poor venous access in two thrombophilic patients. The per-protocol group consisted of all subjects who completed the VOT and underwent measurements of all variables at all sampling time points. Only subjects in the per-protocol group were included in the statistical analysis.
Reagents and Materials
Human α-thrombin was obtained from CellSystems (St. Katharinen, Germany). rAPC (Xigris ® ) was purchased from Eli Lilly (Indianapolis, USA). Argatroban (Argatra ® ) was obtained from Mitsubishi Pharma (Düsseldorf, Germany). Aprotinin (Trasylol   ®   ) was purchased from Bayer (Berlin, Germany). Recombinant hirudin (Refludan ® ) was obtained from Pharmion (Hamburg, Germany). Biotinylated aptamers were synthesized and purified from Microsynth (Balgach, Switzerland). The fluorogenic peptide substrates Pefafluor TH (Thrombin, H-D-CHA-Ala-Arg-AMC) and Pefafluor PCa (APC, Pyr-Pro-Arg-AMC) were purchased from Loxo (Dossenheim, Germany).
Venous Occlusion Testing and Blood Sampling
Baseline blood samples were drawn after 10 minutes of bed rest. Immediately thereafter, VOT was performed in the opposite arm by inflating a blood pressure cuff to 15 mmHg above the diastolic pressure for However, there are no data available showing increased thrombin formation in vivo in relation to venous stasis. This is because it has traditionally not been possible to obtain sensitive measurements of thrombin formation in regions of venous stasis. Measuring the plasma concentrations of the prothrombin fragment 1＋2 (F1＋2) and thrombin-antithrombin complexes (TAT) is useful for assessing the degree of thrombin formation, although this technique has some limitations. First, the limit of quantification (LOQ) of F1＋2 and TAT is 20.0 pmol/L and 20.4 pmol/L, respectively. Second, TAT exclusively represent thrombin inhibited by antithrombin (AT), while thrombin bound to thrombomodulin is not detected. Third, as F1＋2 contains the phospholipid binding motive of prothrombin, it is unclear if a portion of F1＋2 remains bound to activated cell surfaces, resulting in underestimation of the amount of thrombin formed. In order to overcome these limitations, we used highly sensitive oligonucleotide enzyme capture assays (OECAs) to measure the levels of free thrombin and activated protein C (APC) 6, 7) . With a LOQ as low as 0.039 ng/mL (1.08 pmol/L), the thrombin-OECA can detect thrombin with approximately 20 times greater sensitivity than the thrombin markers F1＋2 and TAT 6) . Since APC formation requires the formation of thrombin-thrombomodulin complexes, changes in the plasma levels of APC directly correlate with the amount of thrombin bound to the luminal surface of endothelial cells 7) .
Aim
In the present investigation, the venous occlusion test (VOT) was performed to assess the stasis-related activation of the clotting cascade that may culminate in the generation of thrombin. On the VOT, an upper arm or leg cuff is inflated to between the systolic and diastolic blood pressure, inducing venous stasis for 10-20 minutes 8) . Assessments of blood samples obtained before and during venous occlusion (VO) and from the contralateral arm allow for the evaluation of the regional release of endothelial proteins and changes in the plasma levels of clotting factors and activated clotting factors. The activation of endothelial cells during VO is confirmed by an increase in the level of tissue-type plasminogen activator (t-PA) 9) . Stasis alone is a relatively weak stimulus of thrombus formation. In the Wessler animal model, in which a vascular segment is occluded, hypoxia and stasis alone are insufficient to trigger thrombus formation in the absence of other prothrombotic stimuli 5, 10) . These findings demonstrate that additional acquired or tration range from 0 to 10 ng/mL thrombin (0-272 pmol/L) or rAPC (0-182 pmol/L) were processed in parallel. For the APC OECA, the plasma samples and calibrators were re-calcified prior to the analysis by adding of 1 mol/L of CaCl2, yielding a final concentration of 7.5 mmol/L, in order to improve the binding of APC to the aptamers 7, 11) . Following incubation for two hours at RT, the modules were washed. Subsequently, 100 μL of a fluorogenic substrate solution (100 μmol/L Pefafluor TH or Pefafluor PCa in TBS, pH 8.5, containing 4 mmol/L CaCl2) was added to the wells, and the baseline fluorescence intensity was measured using a plate fluorescence reader (FLx-800, Bio-Tek,Bad Friedrichshall, Germany). Changes in fluorescence over time were evaluated as measurements of the levels of thrombin or APC captured in the wells. The data obtained from the calibrators were interpolated according to a four-parameter curve fit and used to calculate the thrombin and APC concentrations in the samples. The samples and calibrators were assayed in triplicate.
Routine Hemostasis Parameters
The plasma levels of fibrinogen (Clauss method), activity levels of factors (F) II, V, VII, VIII, IX, X, XI, XIII, AT and PC and the antigen levels of von Willebrand factor (VWF) and d-dimer were determined using an automated coagulation analyzer (BCS XP, Siemens Healthcare Diagnostics, Eschborn, Germany) and standard reagents (Multifibren U, Innovin, Actin FSL, Berichrom Factor XIII, Berichrom Antithrombin III, Berichrom Protein C, vWF Ag, INNOVANCE D-Dimer). The plasma levels of F1＋2 and TAT were determined using the Enzygnost F1＋2 (monoclonal) assay and the TAT micro assay, respectively (Siemens Healthcare Diagnostics Products, Marburg, Germany). The plasma levels of t-PA antigen were determined using the TECHNOZYM t-PA Ag ELISA assay (Technoclone, Vienna, Austria), which can detect both the complexed and free forms of the t-PA antigen. The PAP ELISA assay (DRG Instruments, Marburg, Germany) was used to determine the plasma levels of plasmin-α2-antiplasmin (PAP)-complexes.
The study protocol was approved by the Institutional Review Board and Ethics Committee of the University Hospital of Bonn. Informed consent was obtained from all participants in compliance with the Declaration of Helsinki.
Statistical Analysis
Fluid extravasation induced by VO results in hemoconcentration in the occluded vein. Therefore, the concentration of plasma proteins is higher in 12 minutes. Then, with the pressure maintained in the cuff, blood samples were obtained from both arms simultaneously and again 15 minutes after deflation of the cuff from the arm of previous VO. Venipuncture of an antecubital vein was newly performed at each sampling time point using 21-gauge winged infusion sets (Sarstedt, Nümbrecht, Germany). After discharging the first 2 mL, blood was drawn into citrate tubes (final concentration: 10.5 mM, Sarstedt, Nümbrecht, Germany). The tubes contained argatroban (final concentration: 100 μmol/L) for thrombin measurement and aprotinin and r-hirudin (final concentrations: 10 μmol/L and 15 μg/mL, respectively) for APC measurement. The plasma samples were obtained via centrifugation (2,600 x g, 10 min) within 30 minutes and stored at ＜−70 ℃.
Laboratory Methods
Detection of Free Thrombin and APC Using OECA
The OECAs for thrombin and APC detection were performed in the microtiter plate format using white Maxisorp Fluoronunc microtiter modules (Nunc A/S, Roskilde, Denmark), as previously described 6, 7) . For washing, the wells were generally rinsed three times with 300 μL of phosphate-buffered saline (PBS) washing buffer (PBS, 0.05% Tween 20, pH 7.4) using an automated plate washer (SLT Columbus, Tecan, Germany).
The wells were initially coated with 10 μg/mL of bovine serum albumin (BSA)-biotin (100 μL/well) in coating buffer (30 mM Na2CO2, 200 mM NaHCO3, pH 9.0) at 4 ℃ overnight. After washing, 100 μL of PBS washing buffer containing 1 mg/mL of BSA and 10 μg/mL of streptavidin was added to the wells and incubated for one hour at RT. The wells were then blocked using 200 μL/well of blocking buffer (PBS, 20 mg/mL BSA, 0.05% Tween 20, pH 7.4). Following incubation for two hours at RT, the remaining materials were aspirated. For loading the aptamers into the streptavidin-coated wells, either 3'-biotinylated thrombin-aptamers HD1-22 for thrombin-OECA or 3'-biotinylated APC-aptamers HS02-G52 for APC-OECA were diluted in Tris-buffered saline (TBS; pH 7.6, 1 mmol/L each CaCl2 and MgCl2, 0.05% Tween 20, 1 mg/mL BSA), and 100 μL of the solution was added to the wells of streptavidin-primed modules and incubated at RT for one hour. After incubation, the wells were washed with TBS washing buffer (TBS, pH 7.6, 1 mmol/L each CaCl2 and MgCl2, 0.05% Tween 20), and the samples or calibrators were added (100 μL).
Calibration curves covering a 1/2-log10 concen-were considered to be significant after Bonferroni correction.
Results
Study Population
A total of 25 healthy probands (14 women), 15 CAD patients (one woman) and 19 thrombophilic patients (13 women) completed the study. The mean age (range) was 32 (20-58) years among the healthy probands, 65 (48-77) years among the CAD patients and 43 (18-64) years among the thrombophilic patients. Healthy subjects were not treated with anticoagulant or antiplatelet drugs. All patients with CAD plasma samples obtained from an occluded vein than in those obtained from a non-occluded vein. In order to avoid bias due to hemoconcentration, all results were corrected for changes in hematocrit (Ht) in comparison to the baseline values. The degree of blood dilution (Bd) in the sample tubes resulting from the effects of citrate or additional supplements was taken into account by applying the formula F = Ht1(1−Bd× Ht2)/Ht2(1−Bd×Ht1) 12) . All results shown are corrected results. The baseline values were compared with the corrected values obtained at the other sampling time points using the Wilcoxon signed-rank test after the Kruskal-Wallis test to perform the ANOVA. Twotailed tests were used, and only p values of ＜0.0167 ＊ significant increase compared with the baseline value (p＜0.05). ＊ ＊ significant increase compared with the baseline value (p＜0.005). p = 0.0024) and the thrombophilic patients (median t-PA: 2.52 ng/mL, p = 0.005), but not the CAD patients. Furthermore, increased levels of PAP were observed 15 minutes after VO in the healthy probands (median PAP: 592 ng/mL, p = 2×10 −4 ), but not the CAD or thrombophilic patients.
The median VWF in the CAD patients at baseline was 141%, which exceeded the upper reference value of 136%. During VO, a slight but statistically insignificant increase in the median VWF to 153% was observed in the samples obtained from the stasis arm, but not those obtained from the contralateral arm. No changes in VWF were observed 15 minutes after VO in comparison to the baseline values. In addition, the median VWF was not elevated above the reference range in the baseline samples obtained from the healthy probands and thrombophilic patients; this value increased slightly from 90% at baseline to 100% during VO in the healthy probands and 119% to 139% in the thrombophilic patients, although these changes were not significant.
VO Induced Endothelial Activation does not Generate a Prothrombotic Phenotype
In all three groups, the indirect markers of activation of coagulation F1＋2 and TAT did not change significantly during VO, and the median levels remained within their respective reference ranges (＜0.34 nmol/ L for F1＋2, ＜3.9 ng/mL for TAT) at all sampling were under treatment with aspirin, although they did not receive any anticoagulant drugs. Nine of the 19 thrombophilic patients were under treatment with a vitamin K antagonist (VKA); however, none of these subjects received heparin, fondaparinux or antiplatelet drugs. The characteristics of the thrombophilic patients are listed in Supplemental Table 1 .
VO Induces a Profibrinolytic Phenotype
The baseline t-PA levels were lower in the healthy probands (＜0.60 ng/mL, median) than in the CAD patients (1.84 ng/mL) or thrombophilic patients (1.56 ng/mL) ( Table 1) . During VO, the levels of t-PA and PAP increased in all subjects, with the exception of two healthy probands in whom the t-PA levels did not change and a healthy proband and one CAD patient in whom the PAP levels did not increase. The median t-PA level increased to 4.08 ng/mL (p＜1×10 −4 ) in the healthy probands, 9.21 ng/mL (p = 7×10 −4 ) in the CAD patients and 10.25 ng/mL (p= 1×10 −4 ) in the thrombophilic patients (Fig. 1) . Simultaneously, the median PAP increased during VO from 538 to 1,352 ng/mL (p＜1×10 −4 ) in the healthy probands, 543 to 1,107 ng/mL (p = 8×10 −4 ) in the CAD patients and 533 to 1,244 ng/mL in the thrombophilic patients (p = 4×10 −4 ), thus exceeding the normal reference values. A systemic increase in the t-PA level compared to the baseline value was observed 15 minutes after VO in the healthy probands (median t-PA: 0.81 ng/mL, A Box whisker plots of the t-PA plasma levels measured at the stasis arm at baseline and after 12 minutes of VO (12' VO). The center horizontal line is drawn at the median. The top and bottom edges of the boxes are located at the 75th and 25th percentiles of the sample. The top and bottom of the whiskers are located at the 90th and 10th percentiles. Each outlier is shown. B Box whisker plots of the plasma levels of PAP-complexes measured at the stasis arm at baseline and after 12 minutes of VO.
A B (0.017 ng/mL). An increase in the thrombin level to a value higher than the LOQ during VO was observed in one male patient with CAD (4.97 ng/mL) and one female patient with a homozygous FV Leiden mutation who did not receive VKA (1.49 ng/mL). Another patient with CAD displayed a thrombin level above the LOQ 15 minutes after VO. In all other samples, the thrombin levels lay below the LOD. An APC level above the LOQ at baseline was observed in one of the 15 patients with CAD (7%). Meanwhile, an APC level between the LOQ and LOD (0.022 ng/mL) was observed in seven of the 25 healthy probands (28%), six of the 15 CAD patients (40%) and six of the 19 thrombophilic patients (32%). In all other samples, the APC level lay below the LOD at baseline. Similar proportions were observed at the other sampling time points in all cohorts. The same thrombophilic patient who exhibited a thrombin level above the LOQ during VO also showed a quantifiable APC level (1.48 ng/mL).
No subjects had a thrombin or APC level above the LOD or LOQ at more than one sampling time point. Overall, there were no significant changes in the plasma levels of thrombin or APC during or after VO.
The median levels of all other parameters lay within their respective reference ranges at all sampling time points, except for the vitamin K-dependent parameters, which were lower in the thrombophilic time points (Fig. 2) . The patients under VKA treatment exhibited lower F1＋2 values than those not under VKA treatment, although no changes were observed during VO in either subgroup. In addition, no differences were observed in the TAT levels associated with VKA treatment (Supplemental Fig. 1) . In contrast, a slight increase in the d-dimer levels was noted in the samples obtained during VO in all cohorts; however, this increase was not significant in comparison to the baseline values, and the median d-dimer levels were not elevated above the upper reference value of 0.5 μg/mL (0.75 μg/mL for subjects over 60 years of age) at any sampling time point.
Among the healthy probands, a plasma level of thrombin above the LOQ was detected in three of the 25 subjects (12%). Meanwhile, the thrombin levels lay between the LOQ and the limit of detection (LOD: 0.017 ng/mL) in two subjects (8%) and below the LOD in 20 subjects (80%). A similar pattern was observed during VO in the samples obtained from the non-VO arm and the samples obtained 15 minutes after VO (Table 2) . However, during VO, the thrombin levels decreased, resulting in values below the LOD in all samples obtained from the VO arm in the healthy probands.
None of the patients in the CAD or thrombophilic groups exhibited a thrombin level above the LOQ at baseline. Only one patient in the CAD group showed a thrombin concentration above the LOD A Box whisker plots of the F1＋2 plasma levels measured at the stasis arm at baseline and after 12 minutes of VO (12' VO). The center horizontal line is drawn at the median. The top and bottom edges of the boxes are located at the 75th and 25th percentiles of the sample. The top and bottom of the whiskers are located at the 90th and 10th percentiles. Each outlier is shown. B Box whisker plots of the plasma levels of TAT-complexes measured at the stasis arm at baseline and after 12 minutes of VO.
A B be unfavorable. If the clotting cascade is activated during VO, researchers should expect an increase in the plasma levels of free thrombin and the thrombin markers F1 ＋2 and TAT. We recently demonstrated that free thrombin is detectable in patients undergoing major surgery, such as hip and knee replacement, whereas the plasma level of thrombin remains below the LOD of 0.017 ng/mL (0.47 pmol/L) in healthy individuals 6) . In the present study, free thrombin became detectable at the end of VO in none of the healthy probands. In line with this finding, the plasma levels of F1＋2 and TAT remained unchanged, making it most unlikely that short-term VO induces thrombin generation. This conclusion is further supported by the data for the APC measurements, which showed no increases in the APC plasma levels in response to VO, thus ruling out the possibility that thrombin-thrombomodulin complexes were formed.
One may argue that additional inherited or acquired thrombophilic risk factors are required for VO to induce thrombin formation. Therefore, we extended our study to patients with inherited thrombophilic risk factors. Even in the presence of strong thrombophilic risk factors, such as the homozygous FV Leiden mutation or homozygous prothrombin G20210A mutation, there were no indications of thrombin formation. Since these gain-of-function mutations induce hypercoagulability following activation of the coagulation cascade, this finding provides further evidence that the coagulation cascade is not activated in response to short-term venous stasis.
Endothelial cell dysfunction is another risk factor patients who received VKA. No significant changes in these values were observed during VO (Supplemental Table 2 ).
Discussion
Twelve minutes of venous stasis induced the profibrinolytic activation of endothelial cells, as indicated by the release of t-PA and subsequent formation of PAP. These data are consistent with those of previous studies 9, 13) . Although the baseline values for t-PA and PAP were slightly higher among the patients than in the healthy probands, the fibrinolytic response was similar in all three groups, indicating that the release of t-PA from endothelial cells was not influenced by the presence of thrombophilic risk factors or clinically relevant atherosclerosis.
Stimulation of endothelial cells is often associated with the release of VWF stored in Weibel-Palade bodies. A variety of agents that stimulate the release of VWF from endothelial cells have been identified, including thrombin, histamine and the drug desmopressin 14, 15) . There are two possible explanations for the absence of VWF release during VO observed in this study. First, endothelial activation under conditions of stasis stimulates signalling pathways that exclusively lead to the release of t-PA, without involving the activation of Weibel-Palade bodies. Second, the 12-minute stasis period was too short to fully activate endothelial cells. Considering that the release of t-PA that occurs during stasis is part of a countermeasure to prevent fibrin deposition in the resting blood, the concurrent release of profibrinolytic VWF would (20) 25 (23) 23 (19) 22 (21) 25 (18) 25 (17) 24 (16) 25 ( (14) 14 (14) 15 (15) 14 (14) 14 (8) 15 (8) 15 (9) 13 (7)
19 (19) 18 (18) 19 (19) 19 (19) 19 (13) 18 (13) 18 (13) 18 ( 
Conclusion
This study demonstrated that activation of the clotting cascade is not triggered by short-term venous stasis, even in the presence of additional thrombotic risk factors. Moreover, our results suggest that the fibrinolytic response induced by VO is caused by mechanisms independent from thrombin formation. Therefore, the VOT is not useful as a model for simulating the effects of venous stasis on the development of thrombosis. However, this tool is useful for evaluating the fibrinolytic capacity of the endothelium, independent of the fibrinolytic response to coagulation activation.
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potentially contributing to stasis-induced thrombin formation, as such dysfunction may be associated with downregulation of the activatability of the protein-Cpathway and increased binding of neutrophils and monocytes to the altered endothelium, which induces the expression of tissue factor and other procoagulants. In order to extend our study to patients with endothelial dysfunction, we included a group of CAD patients. Recent studies have shown an association between peripheral venous disease and arterial endothelial dysfunction 16, 17) . Therefore, there is strong evidence that endothelial cell dysfunction in CAD patients is not restricted to the arterial endothelial cell lining, justifying the use of these patients as the endothelial damage group in the present study. However, none of the patients in the CAD group showed an increase in thrombin formation.
One limitation of the present study is the relatively short period of venous stasis. The Wessler stasis test shows that clot formation occurs after a stasis time as short as 10 minutes if additional prothrombotic stimuli are present 10) . This demonstrates that, even after short-term venous stasis, hypercoagulable mechanisms may be initiated, implying that the occlusion time of 12 minutes used in the present study was long enough to induce thrombin formation, if present. One may speculate that a profibrinolytic phenotype caused by the release of t-PA is the dominating effect during the first phase of venous stasis, whereas later on, when the t-PA stores in the endothelium are exhausted, procoagulant mechanisms become dominant. This hypothesis may account for the experimental finding that it takes several hours to form thrombi in totally blocked veins and would explain why venous stasis alone is a relatively weak stimulus of thrombus formation 5, 10) . Nevertheless, the profibrinolytic activation of endothelial cells observed in response to short-term venous stasis without concomitant activation of the clotting cascade is an interesting finding. This phenomenon demonstrates that the release of t-PA from endothelial cells during stasis is not a secondary effect associated with the coagulation process. A thrombin level in the picomolar to nanomolar range has been shown to induce acute t-PA release in cultured bovine and human endothelial cells as well as ex vivo animal models [18] [19] [20] [21] . Notably, the thrombin concentrations in these studies were above the LOQ of the OECA. Furthermore, the findings demonstrate, that unlike desmopressin, which stimulates t-PA release together with VWF release from endothelial cells, isolated pharmacological stimulation of t-PA from endothelial cells is achievable. Such an approach may be useful for pre-Short-term venous stasis induces a fibrinolytic activation but not thrombin formation 
